RUMORED BUZZ ON ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS

In Section C, members will receive ABBV-744 and oral navitoclax. In Section D, participants will get ABBV-744 and ruxolitinib. Participants will obtain treatment until eventually ailment progression or the individuals are unable to tolerate the study drugs.- Participant consumed grapefruit or grapefruit products within three days prior to the prima